New AI model predicts susceptibility to over 1,000 diseases - Financial Times
google - New AI model predicts susceptibility to over 1,000 diseases Financial Times
Back to Top / Wednesday, September 17, 2025, 12:21 pm / permalink 14645 / 2 stories in 5 months
ArcaScience raises $7M to expand AI benefit risk platform in drug development
Duncan Riley / siliconangle - French artificial intelligence healthtech startup ArcaScience SAS revealed today that it has raised $7 million in new funding to expand into the U.S. and the U.K., launch a patient-facing solution for pediatric brain cancer and dermatological diseases,and…
Back to Top / Wednesday, September 3, 2025, 4:20 am / permalink 13642 / 2 stories in 6 months
Tahoe Therapeutics clinches $30M for breakthrough AI medical research
Tahoe Therapeutics has secured $30 million in new funding aimed at driving cutting‐edge advancements in medical research through AI. The capital injection will help develop detailed datasets and virtual cell models designed to expedite drug discovery and diagnostics. Not exactly a pill in a bottle, but a promising step forward.
Back to Top / Monday, August 11, 2025, 3:21 pm / permalink 12077 / 1 stories in 6 months
Chai Discovery Raises $70M for AI-Powered Biochemical Innovation
Chai Discovery secured a $70 million Series A to revolutionize the prediction and reprogramming of biochemical molecule interactions. The new funding is set to accelerate its cutting‐edge AI models for therapeutic development and position the company as a serious contender in the competitive health tech landscape.
Back to Top / Thursday, August 7, 2025, 2:21 pm / permalink 11869 / 1 stories in 6 months
Gene scanner pays $9.8 million to get feds off its back in security flap
Brandon Vigliarolo / theregister - Illumina allegedly lied about its testing devices meeting government standards Biotech firm Illumina has agreed to cut the US government a check for the eminently affordable amount of $9.8 million to resolve allegations that it has been selling the feds g…
Back to Top / Thursday, July 31, 2025, 3:21 pm / permalink 11381 / 2 stories in 7 months
EU Rejects Sarepta-Roche Gene Therapy, Triggering Market Plunge
European regulators have denied approval for Sarepta-Roche’s gene therapy candidate, Elevidys, sending the company’s shares tumbling. The decision highlights the regulatory hurdles facing cutting‐edge biotech and the ensuing financial backlash, leaving investors to wonder if innovation comes at too high a price.
Back to Top / Friday, July 25, 2025, 10:21 am / permalink 10913 / 0 stories in 7 months
Latent Labs aims to replace trial-and-error drug discovery with push-button design
Cate Lawrence / tech - Today Latent Labs launches Latent-X, a frontier AI model for push button protein design, which outperforms competing models under identical laboratory conditions. Latent Labs is working to transform t...
Back to Top / Tuesday, July 22, 2025, 3:20 am / permalink 10595 / 3 stories in 7 months
One Biosciences Secures €15M Series A for Precision Oncology
One Biosciences has successfully raised €15 million in a Series A round intended to advance its clinical-grade, single‐cell tumor profiling platform. This funding will drive innovations in precision oncology by supporting enhanced diagnostic capabilities and targeted treatment solutions in the fight against cancer.
Back to Top / Thursday, July 17, 2025, 7:20 am / permalink 10278 / 1 stories in 7 months
New research links caffeine to slower aging at the cellular level
techspot - A recently published study confirms what caffeine enthusiasts have suspected all along: the naturally occurring stimulant is not only great for waking up the mind but may also help keep the body healthier. Researchers are now shedding light on the fascina…
Back to Top / Thursday, June 26, 2025, 4:21 pm / permalink 8942 / 2 stories in 8 months
AlphaGenome: New Google AI Predicts Effects of Genetic Mutations
Markus Kasanmascheff / winbuzzer - Google DeepMind builds on its AlphaFold success with AlphaGenome, a new AI that deciphers the non-coding genome to predict the molecular impact of genetic variations, accelerating the hunt for disease causes and cures.The post AlphaGenome: New Google AI P…
Back to Top / Wednesday, June 25, 2025, 12:20 pm / permalink 8804 / 4 stories in 8 months
23andMe hit with £2.3M fine after exposing genetic data of millions
Connor Jones / theregister - Penalty follows year-long probe into flaws that allowed attack to affect so many The UK's data watchdog is fining beleaguered DNA testing outfit 23andMe £2.31 million ($3.13 million) over its 2023 mega breach.…
Back to Top / Tuesday, June 17, 2025, 9:21 am / permalink 8195 / 5 stories in 8 months
Nonprofit led by 23andMe’s former CEO wins bid to acquire the company
therecord - TTAM Research Institute, led by former 23andMe chief executive Anne Wojcicki, is waiting for a judge to approve its acquisition of the company.
Back to Top / Monday, June 16, 2025, 1:21 pm / permalink 8102 / 2 stories in 8 months
Anne Wojcicki to buy back 23andMe and its data for $305 million
cnbc - Anne Wojcicki to buy back 23andMe and its data for $305 million
Back to Top / Friday, June 13, 2025, 5:20 pm / permalink 7907 / 4 stories in 8 months
Ex-CEO Boosts 23andMe Auction With $305M Bid
23andMe’s auction process has taken an unexpected twist as the company’s former CEO dramatically raised his bid to $305 million—well above the earlier $256 million offer. This bold move intensifies the sale negotiations amid a high-stakes bidding war that could redefine the company’s future fate.
Back to Top / Wednesday, June 4, 2025, 10:20 pm / permalink 6852 / 1 stories in 9 months
Paradromics Completes First Human Brain Implant Test Successfully
In a bold step forward for neurotechnology, Paradromics has reportedly completed its first-ever human brain implant procedure during an epilepsy surgery. This early test marks a significant milestone in bridging brain-computer interfaces, promising to transform how we think about medical innovation—even if it sounds like science fiction brought to life.
Back to Top / Monday, June 2, 2025, 8:20 am / permalink 6455 / 3 stories in 9 months
Regeneron Acquires Bankrupt 23andMe in Auction
In a decisive bankruptcy auction, Regeneron Pharmaceuticals secured the core business assets of 23andMe for $256 million. The acquisition, facilitated via court supervision, signals a strategic expansion into genetic testing services as Regeneron aims to bolster its market position in this competitive field.
Back to Top / Monday, May 19, 2025, 8:20 am / permalink 5007 / 7 stories in 9 months
Novo Nordisk CEO Departs as Bear Market Sends Shockwaves
Facing a brutal downturn in its stock amid a relentless bear market, Novo Nordisk sees its CEO step down in a mutually agreed exit. The leadership shake-up signals more than just market woes—it’s a dramatic pivot in executive strategy for the pharmaceutical titan.
Back to Top / Friday, May 16, 2025, 8:20 am / permalink 4869 / 1 stories in 9 months
Infants Receive Groundbreaking Personalized Gene-Editing Treatment
In an unprecedented medical breakthrough, doctors developed and deployed a tailor-made CRISPR treatment to combat a newborn’s life‐threatening metabolic disorder. The rapid, bespoke therapy marks a pivotal moment in personalized medicine and could signal a new era for addressing rare genetic conditions.
Back to Top / Thursday, May 15, 2025, 1:21 pm / permalink 4812 / 4 stories in 9 months